8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Peptide nano-blanket impedes fibroblasts activation and subsequent formation of pre-metastatic niche

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There is evidence to suggest that the primary tumor induces the formation of a pre-metastatic niche in distal organs by stimulating the production of pro-metastatic factors. Given the fundamental role of the pre-metastatic niche in the development of metastases, interruption of its formation would be a promising strategy to take early action against tumor metastasis. Here we report an enzyme-activated assembled peptide FR17 that can serve as a “flame-retarding blanket” in the pre-metastatic niche specifically to extinguish the “fire” of tumor-supportive microenvironment adaption. We show that the in-situ assembled peptide nano-blanket inhibits fibroblasts activation, suppressing the remodeling of the metastasis-supportive host stromal tissue, and reversing vascular destabilization and angiogenesis. Furthermore, we demonstrate that the nano-blanket prevents the recruitment of myeloid cells to the pre-metastatic niche, regulating the immune-suppressive microenvironment. We show that FR17 administration effectively inhibits the formation of the pulmonary pre-metastatic niche and postoperative metastasis, offering a therapeutic strategy against pre-metastatic niche formation.

          Abstract

          Primary tumors “spread the spark” by establishing a pre-metastatic niche. Here the authors develop an in-situ assembled peptide FR17 to serve as a “flame-retarding blanket” to extinguish the “fire” of the pre-metastatic microenvironment.

          Related collections

          Most cited references68

          • Record: found
          • Abstract: not found
          • Article: not found

          VMD: Visual molecular dynamics

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Myeloid-Derived Suppressor Cells.

              Myeloid cells developed evolutionarily as a major mechanism to protect the host. They evolved as a critical barrier against infections and are important contributors to tissue remodeling. However, in cancer, myeloid cells are largely converted to serve a new master-tumor cells. This process is epitomized by myeloid-derived suppressor cells (MDSC). These cells are closely related to neutrophils and monocytes. MDSCs are not present in the steady state of healthy individuals and appear in cancer and in pathologic conditions associated with chronic inflammation or stress. These cells have emerged as an important contributor to tumor progression. Ample evidence supports a key role for MDSCs in immune suppression in cancer, as well as their prominent role in tumor angiogenesis, drug resistance, and promotion of tumor metastases. MDSCs have a fascinating biology and are implicated in limiting the effects of cancer immunotherapy. Therefore, targeting these cells may represent an attractive therapeutic opportunity. Cancer Immunol Res; 5(1); 3-8. ©2016 AACR.
                Bookmark

                Author and article information

                Contributors
                hanmin@zju.edu.cn
                gaojianqing@zju.edu.cn
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                25 May 2022
                25 May 2022
                2022
                : 13
                : 2906
                Affiliations
                [1 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, , Zhejiang University, ; Hangzhou, 310058 Zhejiang PR China
                [2 ]GRID grid.256112.3, ISNI 0000 0004 1797 9307, Department of Anesthesiology, , Shengli Clinical Medical College, Fujian Medical University, ; Fuzhou, 350001 Fujian PR China
                [3 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, Department of Radiation Oncology, , Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, ; Hangzhou, 310058 Zhejiang PR China
                [4 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, Cancer Center of Zhejiang University, Zhejiang University, ; Hangzhou, 310058 Zhejiang PR China
                [5 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, Hangzhou Institute of Innovative Medicine, Zhejiang University, ; Hangzhou, 310058 Zhejiang PR China
                Author information
                http://orcid.org/0000-0002-4834-6946
                http://orcid.org/0000-0001-9373-8466
                Article
                30634
                10.1038/s41467-022-30634-8
                9132894
                35614076
                f0573063-b300-434a-b988-d2b79677496a
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 4 August 2021
                : 10 May 2022
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100001809, National Natural Science Foundation of China (National Science Foundation of China);
                Award ID: 81673022
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                Uncategorized
                metastasis,pharmaceutics,cancer prevention,rna sequencing
                Uncategorized
                metastasis, pharmaceutics, cancer prevention, rna sequencing

                Comments

                Comment on this article